Comparison Overview

Arch Pharmalabs, Ltd.

VS

Ranbaxy

Arch Pharmalabs, Ltd.

"H" Wing, 4th Floor, Tex Centre, Andheri (E), Mumbai, undefined, 400 072, IN
Last Update: 2025-03-05 (UTC)

Founded in 1999,Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres. Arch Pharmalabs works tirelessly to deliver value, innovation and effective supply chain solutions in the spirit of true partnership. Our large family of satisfied customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a Preferred Supplier or Strategic Partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 678
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Ranbaxy

Plot No. 90 Sector 32 Gurgaon, Haryana 122001, IN
Last Update: 2025-05-06 (UTC)
Between 750 and 799

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing. Vision & Aspirations Ranbaxy is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. The Company aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012. Financials Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn, reflecting a growth of 4%. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2008, North America, the Company's largest market contributed sales of US $ 449 Mn, followed by Europe garnering US $ 330 Mn. Business in Asia has been going strong with India clocking sales of around US $ 300 Mn with market leadership in several business segments, backed by strong brand-building skills.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ranbaxy.jpeg
Ranbaxy
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Arch Pharmalabs, Ltd.
100%
Compliance Rate
0/4 Standards Verified
Ranbaxy
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Arch Pharmalabs, Ltd. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ranbaxy in 2025.

Incident History — Arch Pharmalabs, Ltd. (X = Date, Y = Severity)

Arch Pharmalabs, Ltd. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Ranbaxy (X = Date, Y = Severity)

Ranbaxy cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
Incidents

No Incident

https://images.rankiteo.com/companyimages/ranbaxy.jpeg
Ranbaxy
Incidents

No Incident

FAQ

Ranbaxy company demonstrates a stronger AI Cybersecurity Score compared to Arch Pharmalabs, Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Ranbaxy company has disclosed a higher number of cyber incidents compared to Arch Pharmalabs, Ltd. company.

In the current year, Ranbaxy company and Arch Pharmalabs, Ltd. company have not reported any cyber incidents.

Neither Ranbaxy company nor Arch Pharmalabs, Ltd. company has reported experiencing a ransomware attack publicly.

Neither Ranbaxy company nor Arch Pharmalabs, Ltd. company has reported experiencing a data breach publicly.

Neither Ranbaxy company nor Arch Pharmalabs, Ltd. company has reported experiencing targeted cyberattacks publicly.

Neither Arch Pharmalabs, Ltd. company nor Ranbaxy company has reported experiencing or disclosing vulnerabilities publicly.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Arch Pharmalabs, Ltd. company nor Ranbaxy company has publicly disclosed detailed information about the number of their subsidiaries.

Arch Pharmalabs, Ltd. company employs more people globally than Ranbaxy company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds SOC 2 Type 1 certification.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds SOC 2 Type 2 certification.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds ISO 27001 certification.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds PCI DSS certification.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds HIPAA certification.

Neither Arch Pharmalabs, Ltd. nor Ranbaxy holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X